Study Suggests Part D Payers’ Prior Authorization Policies for New Drugs May Be Too Strict
Most new drugs covered under Medicare Part D are subject to prior authorization (PA) requirements, largely due to their high launch prices. A recent study published in JAMA Health Forum observed that these policies are frequently inconsistent across payers and may prove too burdensome for patients and providers.
Researchers identified drugs approved between 2013 and 2017 and reviewed the 2020 formularies of the eight largest Part D payers, which cover about 90% of all Part D beneficiaries. They compared PA policies to each drug’s FDA-approved indications and noted if payers mirrored the approved labeling or were more restrictive than the drug’s label. Researchers observed substantial variation in the frequency and type of PA across payers, and they found that about 40% of the new drugs had PA criteria that went beyond the drug’s labeling.
Related Posts

Part D Changes in Inflation Reduction Act Could Lead to Tighter Formulary Management
READ MORE
MA, Part D Plans Face New Premium Calculus With Drug Price Negotiation
READ MORE